Literature DB >> 347289

Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation.

R Parkman, J Rappeport, R Geha, J Belli, R Cassady, R Levey, D G Nathan, F S Rosen.   

Abstract

Two patients with the Wiskott-Aldrich syndrome had complete donor lymphoid and hematopoietic engraftment after successful allogeneic bone-marrow transplantation. One patient had had only a temporary donor T-lymphocyte graft after a previous transplantation, for which he had been prepared with cytarabine and cyclophosphamide; the patient's own T lymphocytes returned six months later. A repeat transplant, for which the patient was prepared with anti-human thymocyte serum, total-body irradiation and procarbazine, resulted in complete donor engraftment. The second patient underwent a successful transplantation after similar preparation, except that procarbazine was omitted. At 11 and five months after transplantation both had normal hematopoiesis and no evidence of graft-versus-host disease. This treatment of the Wiskott-Aldrich syndrome may be a model for the correction of other genetically determined immune and hematologic bone-marrow disorders.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 347289     DOI: 10.1056/NEJM197804272981701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Management of Wiskott-Aldrich syndrome.

Authors:  A Srivastava; H A Swaid; M Kabra; I C Verma
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

Review 2.  Bone marrow transplantation: a review.

Authors:  R E Hardy; E V Ikpeazu
Journal:  J Natl Med Assoc       Date:  1989-05       Impact factor: 1.798

Review 3.  Wiskott-Aldrich syndrome: a multidisciplinary disease.

Authors:  G R Standen
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

4.  Germ-line mosaicism simulates genetic heterogeneity in Wiskott-Aldrich syndrome.

Authors:  B Arveiler; G de Saint-Basile; A Fischer; C Griscelli; J L Mandel
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

Review 5.  Stem cell transplantation for immunodeficiency.

Authors:  A Fischer; E Haddad; N Jabado; J L Casanova; S Blanche; F Le Deist; M Cavazzana-Calvo
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Transfer factor therapy in hyperimmunoglobulinaemia E syndrome.

Authors:  H H Kesarwala; R V Prasad; R Szep; E Oldman; S Lane; P S Papageorgiou
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

7.  Long-term immunological reconstitution by peripheral blood leucocytes in severe combined immune deficiency disease: implications for the role of mature lymphocytes in histocompatible bone marrow transplantation.

Authors:  S H Polmar; B Z Schacter; R U Sorensen
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

8.  Wiskott-Aldrich syndrome carrier detection with the hypervariable marker M27 beta.

Authors:  G de Saint Basile; L D Notarangelo; C Bonaiti-Pellié; M Doussau; O Prolini; I W Craig; A Ugazio; C Griscelli; A Fischer
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

9.  Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population.

Authors:  Marco Marziali; Antonella Isgrò; Javid Gaziev; Guido Lucarelli
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-26       Impact factor: 2.576

10.  A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole.

Authors:  L Businco; F Laurenti; P Rossi; E Galli; F Aiuti
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.